<DOC>
	<DOCNO>NCT00002908</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness bryostatin 1 treat patient relapse non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Bryostatin 1 Treating Patients With Relapsed Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy bryostatin 1 administer 72-hour infusion patient relapse non-Hodgkin 's lymphoma chronic lymphocytic leukemia . II . Gain information regard toxicity tolerability escalate vincristine dos give bryostatin 1 infusion cohort patient fail respond bryostatin alone . III . Determine qualitative quantitative toxic effect bryostatin 1 patient . IV . Determine duration response survival follow treatment bryostatin 1 . OUTLINE : All patient receive bryostatin 1 72-hour continuous infusion every 2 week disease progression 2 course beyond documentation complete remission . Response assess every 4 course . Patients disease progression continue meet eligibility criterion receive vincristine within 2 hour completion bryostatin 1 infusion . Groups 3-6 patient receive escalate dos vincristine maximum tolerate dose bryostatin 1 determine . Courses repeat every 2 week , ; individual dose escalation allow . No concurrent steroid permit . Patients follow survival . PROJECTED ACCRUAL : A total 25 evaluable patient low-grade NHL CLL enter approximately 20 month 2-4 response first 15 patient . A total 20 evaluable patient intermediate- high-grade NHL enter approximately 2 year 1 2 response first 10 patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow hematologic malignancy fail 1 2 prior frontline chemotherapy regimens ineligible treatment high potential efficacy : Histologically confirm chronic lymphocytic leukemia ( CLL ) Intermediate highrisk ( RAI stage IIV ) disease Evidence active disease require least one follow intermediaterisk CLL : One follow B symptom : Weight loss 10 % previous 6 month Extreme fatigue Fever 100 F without evidence infection Night sweat Massive ( 6 cm leave costal margin ) progressive splenomegaly Massive ( 10 cm long diameter ) progressive lymphadenopathy Progressive lymphocytosis 50 % increase 2month period anticipate doubling time le 12 month Progressive bone marrow failure manifest development worsen anemia and/or thrombocytopenia Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid Biopsy proven low , intermediate , highgrade nonHodgkin 's lymphoma Transformed lymphoma allow Measurable disease require Retreatment study allow disease relapse complete remission PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : ANC least 1,500/mm3 ( least 1,000/mm3 CLL patient least 30 % marrow involvement ) Platelets least 100,000/mm3 ( least 50,000/mm3 CLL patient least 30 % marrow involvement ) Hepatic : Bilirubin le 1.5 mg/dL Transaminases le 2.5 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history impair cardiac status , e.g . : Severe coronary artery disease Cardiomyopathy Uncontrolled congestive heart failure Arrhythmia Other : No known AIDS HIV infection No second malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer In situ cervical cancer Not pregnant nursing Effective contraception require fertile patient 2 month study PRIOR CONCURRENT THERAPY : No concurrent therapy Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since chemotherapy ( 8 week since nitrosoureas mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since radiotherapy recover Surgery : Not specify Other : No prior bone marrow transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>